CDK13

Summary

CDK13 (cyclin dependent kinase 13, HGNC:1733) is a protein-coding gene on chromosome 7p14.1, encoding Cyclin-dependent kinase 13 (Q14004). Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. It is haploinsufficient (ClinGen: sufficient evidence).

The protein encoded by this gene is a member of the cyclin-dependent serine/threonine protein kinase family. Members of this family are well known for their essential roles as master switches in cell cycle control. The exact function of this protein has not yet been determined, but it may play a role in mRNA processing and may be involved in regulation of hematopoiesis. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 8621 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic intellectual disability (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 5
• Clinical variants (ClinVar): 1,264 total — 40 pathogenic, 42 likely-pathogenic (top 2% of genes corpus-wide)
• Regional missense constraint (gnomAD): 2 of 5 regions constrained (≈20% of expected missense variation)
• GTEx eGene: eQTL in 12 tissues, sQTL in 2 (q < 0.05)
• Phenotypes (HPO): 67
• ChEMBL bioactivity: 20 clinical-phase molecules tested; no curated mechanism-of-action drug
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.43 (moderately constrained)
• MANE Select transcript: NM_003718

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1733
Approved symbol	CDK13
Name	cyclin dependent kinase 13
Location	7p14.1
Locus type	gene with protein product
Status	Approved
Aliases	CHED, CDC2L, KIAA1791
Ensembl gene	ENSG00000065883
Ensembl biotype	protein_coding
OMIM	603309
Entrez	8621

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 13 protein_coding, 6 retained_intron, 6 protein_coding_CDS_not_defined

MANE Select: ENST00000181839

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 4: 1

ENST00000181839, ENST00000340829, ENST00000465643, ENST00000478563, ENST00000484589, ENST00000642213, ENST00000642592, ENST00000642626, ENST00000642660, ENST00000643859, ENST00000643868, ENST00000643915, ENST00000644221, ENST00000644561, ENST00000645470, ENST00000645826, ENST00000646039, ENST00000646437, ENST00000647453, ENST00000647518, ENST00000700485, ENST00000700486, ENST00000700487, ENST00000966764, ENST00001139842

RefSeq mRNA: 2 — MANE Select: NM_003718 NM_003718, NM_031267

CCDS: CCDS5461, CCDS5462

Canonical transcript exons

ENST00000181839 — 14 exons

Exon	Start	End
ENSE00000521990	40078720	40078851
ENSE00000832466	40078005	40078121
ENSE00000832468	40092785	40093237
ENSE00001709712	39987599	39988258
ENSE00001886832	39950256	39951852
ENSE00003494733	40045836	40046025
ENSE00003525244	39997494	39997664
ENSE00003581011	40062826	40062927
ENSE00003586066	40001861	40002031
ENSE00003592719	40063023	40063100
ENSE00003629850	40047821	40047877
ENSE00003674806	39999361	39999500
ENSE00003687550	40088126	40088331
ENSE00004795686	40094130	40099580

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 99.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.1769 / max 371.8702, expressed in 1813 samples.

Highest expression (Bgee): buccal mucosa cell, renal medulla, visceral pleura, pylorus, nipple.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CDK13 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 12 tissues and its splicing (sQTL) in 2 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

14 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells EBV-transformed lymphocytes	eqtl	6.3e-08	+0.27	7:39945120:C:T
Nerve Tibial	eqtl	1.6e-05	-0.13	7:40055042:A:G
Cells Cultured fibroblasts	eqtl	2.6e-03	-0.10	7:39875962:A:C
Brain Cerebellar Hemisphere	eqtl	1.0e-02	+0.60	7:40455411:G:T
Brain Putamen basal ganglia	eqtl	1.4e-02	-0.82	7:39049161:G:A
Testis	eqtl	1.7e-02	-0.09	7:39875962:A:C
Esophagus Muscularis	eqtl	2.2e-02	-0.12	7:40046166:C:T
Brain Anterior cingulate cortex BA24	eqtl	2.3e-02	-0.81	7:40872908:AGAACTGAGGTG:A
Whole Blood	eqtl	2.9e-02	+0.07	7:39809989:T:C
Cells Cultured fibroblasts	sqtl	3.4e-02	-1.11	7:39766413:A:G
Heart Atrial Appendage	eqtl	3.7e-02	-0.26	7:40124831:C:T
Brain Cerebellum	eqtl	3.8e-02	+0.93	7:39828382:C:T
Artery Tibial	eqtl	4.2e-02	+0.36	7:40321424:C:T
Cells EBV-transformed lymphocytes	sqtl	4.3e-02	+1.33	7:39897537:T:A

FANTOM5 promoters

8 alternative TSS:

Promoter ID	TPM avg	Samples expressed
78276	7.6433	1635
78274	7.3987	1774
78275	4.2767	1693
78273	1.8750	934
78279	1.0764	569
78277	0.4641	185
78278	0.3132	130
78280	0.1295	41

Top tissues by expression

showing 100 of 300 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	99.82	gold quality
renal medulla	UBERON:0000362	99.69	gold quality
visceral pleura	UBERON:0002401	99.67	gold quality
pylorus	UBERON:0001166	99.55	gold quality
nipple	UBERON:0002030	99.51	gold quality
endothelial cell	CL:0000115	99.47	gold quality
cardia of stomach	UBERON:0001162	99.47	gold quality
ventral tegmental area	UBERON:0002691	99.46	gold quality
inferior vagus X ganglion	UBERON:0005363	99.43	gold quality
parietal pleura	UBERON:0002400	99.42	gold quality
lateral globus pallidus	UBERON:0002476	99.40	gold quality
superior surface of tongue	UBERON:0007371	99.39	gold quality
trigeminal ganglion	UBERON:0001675	99.38	gold quality
subthalamic nucleus	UBERON:0001906	99.37	gold quality
superior vestibular nucleus	UBERON:0007227	99.37	gold quality
tibia	UBERON:0000979	99.34	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.30	gold quality
substantia nigra pars compacta	UBERON:0001965	99.26	gold quality
pericardium	UBERON:0002407	99.06	gold quality
urethra	UBERON:0000057	98.99	gold quality
penis	UBERON:0000989	98.91	gold quality
superficial temporal artery	UBERON:0001614	98.85	gold quality
tendon of biceps brachii	UBERON:0008188	98.85	gold quality
synovial joint	UBERON:0002217	98.83	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.80	gold quality
adult organism	UBERON:0007023	98.80	gold quality
saphenous vein	UBERON:0007318	98.79	gold quality
pharyngeal mucosa	UBERON:0000355	98.78	gold quality
pleura	UBERON:0000977	98.76	gold quality
caput epididymis	UBERON:0004358	98.60	gold quality
body of tongue	UBERON:0011876	98.55	gold quality
mucosa of paranasal sinus	UBERON:0005030	98.51	gold quality
pons	UBERON:0000988	98.45	gold quality
mammalian vulva	UBERON:0000997	98.45	gold quality
oral cavity	UBERON:0000167	98.43	gold quality
tongue	UBERON:0001723	98.43	gold quality
seminal vesicle	UBERON:0000998	98.34	gold quality
bronchial epithelial cell	CL:0002328	98.30	gold quality
globus pallidus	UBERON:0001875	98.30	gold quality
sperm	CL:0000019	98.29	gold quality
cauda epididymis	UBERON:0004360	98.29	gold quality
jejunal mucosa	UBERON:0000399	98.25	gold quality
germinal epithelium of ovary	UBERON:0001304	98.22	gold quality
skin of hip	UBERON:0001554	98.19	gold quality
jejunum	UBERON:0002115	98.16	gold quality
trabecular bone tissue	UBERON:0002483	98.13	gold quality
vena cava	UBERON:0004087	98.12	gold quality
corpus epididymis	UBERON:0004359	98.08	gold quality
medial globus pallidus	UBERON:0002477	98.01	gold quality
upper leg skin	UBERON:0004262	97.47	gold quality
epithelium of nasopharynx	UBERON:0001951	97.41	gold quality
dorsal root ganglion	UBERON:0000044	97.40	gold quality
nasopharynx	UBERON:0001728	97.39	gold quality
tendon	UBERON:0000043	97.23	gold quality
pigmented layer of retina	UBERON:0001782	97.21	gold quality
retina	UBERON:0000966	97.18	gold quality
calcaneal tendon	UBERON:0003701	96.79	gold quality
corpus callosum	UBERON:0002336	96.70	gold quality
lower lobe of lung	UBERON:0008949	96.46	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.39	gold quality
pancreatic ductal cell	CL:0002079	96.25	gold quality
parietal lobe	UBERON:0001872	96.09	gold quality
mammary duct	UBERON:0001765	95.96	gold quality
tonsil	UBERON:0002372	95.94	gold quality
dorsal plus ventral thalamus	UBERON:0001897	95.89	gold quality
male germ cell	CL:0000015	95.79	gold quality
medulla oblongata	UBERON:0001896	95.64	gold quality
postcentral gyrus	UBERON:0002581	95.44	gold quality
gingival epithelium	UBERON:0001949	95.41	gold quality
entorhinal cortex	UBERON:0002728	95.04	gold quality
biceps brachii	UBERON:0001507	94.92	gold quality
cartilage tissue	UBERON:0002418	94.92	gold quality
adrenal tissue	UBERON:0018303	94.83	gold quality
endometrium	UBERON:0001295	94.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	94.53	gold quality
epithelium of mammary gland	UBERON:0003244	94.48	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.38	gold quality
bronchus	UBERON:0002185	94.13	gold quality
mammary gland	UBERON:0001911	94.11	gold quality
gingiva	UBERON:0001828	94.10	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.05	gold quality
colonic epithelium	UBERON:0000397	94.04	gold quality
cervix squamous epithelium	UBERON:0006922	94.04	gold quality
thoracic mammary gland	UBERON:0005200	94.02	gold quality
bone element	UBERON:0001474	94.01	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.01	gold quality
epithelium of bronchus	UBERON:0002031	93.94	gold quality
lower esophagus mucosa	UBERON:0035834	93.81	gold quality
colonic mucosa	UBERON:0000317	93.73	gold quality
occipital lobe	UBERON:0002021	93.72	gold quality
amniotic fluid	UBERON:0000173	93.70	gold quality
squamous epithelium	UBERON:0006914	93.64	gold quality
superior frontal gyrus	UBERON:0002661	93.58	gold quality
eye	UBERON:0000970	93.56	gold quality
right uterine tube	UBERON:0001302	93.51	gold quality
uterus	UBERON:0000995	93.41	gold quality
oviduct epithelium	UBERON:0004804	93.39	gold quality
sural nerve	UBERON:0015488	93.30	gold quality
ovary	UBERON:0000992	93.24	gold quality
tongue squamous epithelium	UBERON:0006919	93.09	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-75140	no	614.20
E-MTAB-2983	no	279.94
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Cerebellum	tissue	109.0	not detected
Putamen	tissue	69.7
Hypothalamus	tissue	65.8
Pons	tissue	64.6
Septum	tissue	62.7
Basal ganglia	tissue	62.3	not detected
Nucleus accumbens	tissue	61.4
Ventral forebrain	tissue	59.3
Periaqueductal gray	tissue	56.9
Thalamus	tissue	55.8
Superior colliculi	tissue	55.6
Cerebral cortex	tissue	55.5	not detected
Occipital cortex	tissue	55.5
Substantia nigra	tissue	55.4
Choroid plexus	tissue	55.0
Prefrontal cortex	tissue	54.6
Motor cortex	tissue	54.6
Midbrain	tissue	54.3
Amygdala	tissue	53.3
Hippocampus	tissue	52.9	not detected
Hippocampal formation	tissue	52.4
Entorhinal cortex	tissue	52.4
Locus coeruleus	tissue	51.4
Olfactory bulb	tissue	51.1
Medulla oblongata	tissue	50.8
Postcentral gyrus	tissue	49.6
Somatosensory cortex	tissue	49.3
Insular cortex	tissue	49.1
Temporal cortex	tissue	48.9
Spinal cord	tissue	48.4
Retrosplenial and cingulate cortex	tissue	47.9
Retrosplenial cortex	tissue	47.7
Corpus callosum	tissue	45.2
Bone marrow	tissue	26.1	not detected
Lymph node	tissue	18.6	not detected
Thyroid gland	tissue	18.0	not detected
Retina	tissue	17.5
Tonsil	tissue	17.3	low
Caudate putamen	tissue	17.0
Testis	tissue	16.5	high
Thymus	tissue	16.1
Frontal cortex	tissue	15.7
Spleen	tissue	15.0	not detected
Parathyroid gland	tissue	14.7
Liver	tissue	14.2	not detected
Ovary	tissue	13.3	not detected
Fallopian tube	tissue	13.1	medium
Epididymis	tissue	13.0	not detected
Appendix	tissue	12.9	low
Placenta	tissue	12.4	low
Vagina	tissue	12.3	medium
Esophagus	tissue	12.2	low
Tongue	tissue	12.2
Endometrium 1	tissue	11.9	not detected
Rectum	tissue	11.8	medium
Stomach 1	tissue	11.3	medium
Pancreas	tissue	11.3	not detected
Kidney	tissue	11.3	high
Salivary gland	tissue	11.2	not detected
Gallbladder	tissue	11.1	not detected

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Flocculonodular lobe (79.2), Vermis (77.7), Cerebellar cortex (77.5), Parieto-temporal junction (white matter) (68.4), Temporal white matter (68.2).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting CDK13 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 185 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-205-3P	99.92	69.92	3165

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.434, missense Z -1.11 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000181839 splits into 5 regions with different missense tolerance; 2 are missense-constrained (≈20% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
7:39,950,642–39,997,634	1051 / 931.0	1.13	no
7:39,997,635–40,078,720	130 / 362.4	0.36	yes (p 2.9e-34)
7:40,078,721–40,078,850	45 / 57.0	0.79	no
7:40,078,851–40,088,185	3 / 22.1	0.14	yes (p 4.8e-05)
7:40,088,186–40,094,977	475 / 579.3	0.82	no
ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 24)

• Data demonstrate that CDC2L5 is located in the nucleoplasm, where it directly interacts with the ASF/SF2-associated protein p32, a protein involved in splicing regulation. (PMID:16721827)
• CDK13 interacts with cyclin K, and is required for self-renewal in ES cells. (PMID:22547058)
• Coincidently amplified CDK13, GMNN, and CENPF genes can play a role as common cancer-driver genes in human cancers. (PMID:22912832)
• High CDK13 expression is associated with pancreatic cancer. (PMID:25216700)
• CDK12 and CDK13 losses in HCT116 cells preferentially affect expression of DNA damage response. (PMID:25561469)
• CDK13 gene is amplified in different types of cancer indicate that this kinase can contribute to cancer development in human. (PMID:26886422)
• Mutation in CHK13 gene is associated with congenital heart defects. (PMID:27479907)
• Detailed phenotypic and molecular characterisation of 9 individuals with pathogenic variants in CDK13 is provided. Two individuals had novel CDK13 variants (p.Asn842Asp, p.Lys734Glu), while the remaining seven unrelated individuals had a recurrent, previously published p.Asn842Ser variant. (PMID:28807008)
• heterozygous, likely dominant negative mutations affecting the protein kinase domain of the CDK13 gene result in a recognisable, syndromic form of intellectual disability, with or without congenital heart disease. (PMID:29021403)
• Heterozygous constitutional CDK13 mutations in 3 patients cause intellectual disability without cardiac defects. (PMID:29222009)
• We demonstrate the synthesis of two aberrant CDK13 transcripts in lymphoblastoid cells from an individual with a splice-site variant. Clinical characteristics of the individuals include mild to severe intellectual disability (ID), developmental delay, behavioural problems, (neonatal) hypotonia and a variety of facial dysmorphism. (PMID:29393965)
• CDK13 RNA over-editing sites mediated by ADAR1 may serve as novel cancer driver events in HCC progression. (PMID:29996118)
• CDK13 is important for proper expression of a number of genes, but it also probably plays yet-to-be-discovered roles in other processes. (PMID:30319007)
• Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. (PMID:31297882)
• Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1alpha and beclin1 in Breast Cancer Patients. (PMID:33292020)
• CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. (PMID:33390186)
• Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13. (PMID:33879837)
• HIV-1 Nef interacts with the cyclin K/CDK13 complex to antagonize SERINC5 for optimal viral infectivity. (PMID:34380030)
• An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks. (PMID:34496885)
• CDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature. (PMID:35063350)
• CDK13-related disorder: a deep characterization of speech and language abilities and addition of 33 novel cases. (PMID:36599938)
• CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1. (PMID:37026485)
• Oncogenic CDK13 mutations impede nuclear RNA surveillance. (PMID:37079685)
• CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. (PMID:37845385)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdk13	ENSDARG00000076791
mus_musculus	Cdk13	ENSMUSG00000041297
rattus_norvegicus	Cdk13	ENSRNOG00000013620
drosophila_melanogaster	Cdk12	FBGN0037093

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK11A (ENSG00000008128), CDK14 (ENSG00000058091), CDK17 (ENSG00000059758), CDKL1 (ENSG00000100490), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1916812) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 33 distinct phenotype terms.

Mouse phenotype (MP)	Records
midline facial cleft	1
abnormal blood flow velocity	1
abnormal heart morphology	1
thin ventricular wall	1
abnormal kidney development	1
delayed kidney development	1
abnormal liver development	1
small liver	1
decreased brain size	1
increased startle reflex	1
irregular heartbeat	1
decreased embryo size	1
delayed brain development	1
small heart	1
thin myocardium	1
small kidney	1
small lung	1
abnormal capillary morphology	1
abnormal facial morphology	1
embryonic growth retardation	1
abnormal heart ventricle morphology	1
pericardial effusion	1
abnormal myocardium layer morphology	1
abnormal palate development	1
abnormal secondary palate development	1

+8 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Oryza sativa Indica Group	A2XUW1	100.0%	Diamond
Oryza sativa Japonica Group	Q7XUF4	100.0%	Diamond
Bos taurus	Q5EAB2	99.5%	Diamond
Macaca mulatta	Q5EDC3	99.4%	Diamond
Pongo abelii	Q5R754	98.4%	Diamond
Xenopus laevis	Q4V862	97.9%	Diamond
Xenopus tropicalis	Q6GLD8	97.9%	Diamond
Gallus gallus	Q5ZKN1	94.9%	Diamond
Ailuropoda melanoleuca	D2H526	92.5%	Diamond
Lathyrus oleraceus	P28567	90.8%	Diamond
Oryctolagus cuniculus	Q9TTK0	90.5%	Diamond
Arabidopsis thaliana	Q8W4P1	89.4%	Diamond
Macaca fascicularis	Q4R7T5	89.3%	Diamond
Aspergillus fumigatus Af293	Q4WTN5	87.2%	Diamond
Aspergillus nidulans FGSC A4	Q96VK3	87.2%	Diamond
Saccharomyces cerevisiae S288C	P23293	72.2%	Diamond
Nakaseomyces glabratus CBS 138	Q6FQ83	72.2%	Diamond
Eremothecium gossypii ATCC 10895	Q75D46	70.0%	Diamond
Kluyveromyces lactis NRRL Y-1140	Q6CRA9	68.6%	Diamond
Debaryomyces hansenii CBS767	Q6BV06	68.2%	Diamond
Candida albicans SC5314	Q9Y7W4	68.2%	Diamond
Neurospora crassa OR74A	Q871M9	67.7%	Diamond
Fusarium graminearum PH-1	Q4I5U9	67.6%	Diamond
Dictyostelium discoideum	Q75JN1	59.6%	Diamond
Caenorhabditis elegans	Q23357	58.2%	Diamond
Schizosaccharomyces pombe 972h-	Q96WV9	56.9%	Diamond
Yarrowia lipolytica CLIB122	Q6C842	52.0%	Diamond
Encephalitozoon cuniculi GB-M1	Q8SR90	43.4%	Diamond
Invertebrate iridescent virus 6	Q91FD5	53.7%	Diamond
Fowlpox virus strain NVSL	Q9J523	48.9%	Diamond
Acanthamoeba polyphaga mimivirus	Q5UNT1	37.9%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
CDK13-DT	ncRNA	112267983
MPLKIP	protein-coding	136647
SUGCT	protein-coding	79783
LINC00265	ncRNA	349114

Protein

Protein identifiers

Cyclin-dependent kinase 13 — Q14004 (reviewed: Q14004)

Alternative names: CDC2-related protein kinase 5, Cell division cycle 2-like protein kinase 5, Cell division protein kinase 13, Cholinesterase-related cell division controller

All UniProt accessions (10): A0A2R8Y4Z0, A0A2R8Y644, A0A2R8Y7W5, A0A2R8Y7Y0, A0A2R8YCQ1, A0A2R8YD28, A0A2R8YEB7, A0A2R8YF61, A0A2R8YFE7, Q14004

UniProt curated annotations — full annotation on UniProt →

Function. Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at ‘Lys-50’ and ‘Lys-51’, thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef.

Subunit / interactions. (Microbial infection) Interacts with human herpes virus 1 (HHV-1) transcriptional regulator ICP22. Interacts with CCNL1 and CCNL2. Interacts with CCNK. Interacts with C1QBP. (Microbial infection) Interacts with HIV-1 Tat.

Subcellular location. Nucleus speckle.

Tissue specificity. Expressed in fetal brain, liver, muscle and in adult brain. Also expressed in neuroblastoma and glioblastoma tumors.

Disease relevance. Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD) [MIM:617360] An autosomal dominant syndrome characterized by atrial and/or ventricular septal congenital heart defects, facial dysmorphism with hypertelorism, upslanted palpebral fissures, epicanthal folds, ptosis, strabismus, posteriorly rotated ears, thin upper lip, and small mouth. Patients manifest global developmental delay, delayed walking and speech acquisition, and intellectual disability. Some patients have mild microcephaly, a small cerebral cortex, and agenesis of corpus callosum. More variable features include clinodactyly and/or camptodactyly of the fingers, hypotonia, and joint hypermobility. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14004-1	1	yes
Q14004-2	2

RefSeq proteins (2): NP_003709, NP_112557 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR050108	CDK	Family

Pfam: PF00069

Enzyme classification (BRENDA)

• EC 2.7.11.22 — cyclin-dependent kinase (BRENDA: 49 organisms, 441 substrates, 555 inhibitors, 8 Km, 4 kcat entries)
• EC 2.7.11.23 — [RNA-polymerase]-subunit kinase (BRENDA: 12 organisms, 155 substrates, 47 inhibitors, 15 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.01–0.06	6
ADAQHATPPKKKRKVEDPKDF	0.046–0.521	2
ATP	0.0052–0.017	2
HEPTA-SIX PEPTIDE	0.189–0.2	2
L-ARG-HEPTA PEPTIDE	0.212–0.243	2
FIN1	0.003	1
PKTPKKAKKL	0.0029	1
CTD-CONTAINING FUSION PROTEIN	0.0002	1
GTP	0.18	1
SYNTHETIC PEPTIDE	0.15	1
[DNA-DIRECTED RNA POLYMERASE]	0.0001	1

Catalyzed reactions (Rhea)

• [DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed RNA polymerase] + ADP + H(+) (RHEA:10216)
• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (121 total): compositionally biased region 21, modified residue 20, helix 19, sequence variant 18, region of interest 11, strand 11, turn 7, sequence conflict 6, binding site 2, cross-link 2, chain 1, domain 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures by resolution:

PDB	Title	Method	Resolution (Å)
5EFQ	Crystal structure of human Cdk13/Cyclin K in complex with ADP-aluminum fluoride	X-RAY DIFFRACTION	2
7NXJ	Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531	X-RAY DIFFRACTION	2.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14004-F1	50.59	0.19

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Kinases, CMGC Ser/Thr protein kinases, Predicted intracellular proteins, Disease related genes, Potential drug targets, Human disease related genes, Congenital malformations, Congenital malformations of the circulatory system

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nuclear speckles; cytosol; golgi apparatus

Antibody reliability (HPA): IH uncertain · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
837	proton acceptor

Ligand- & substrate-binding residues (2)

Position	Role
711–719	ATP
734	ATP

Post-translational modifications (22)

Type	Positions
Phosphoserine	315, 317, 325, 340, 342, 358, 360, 383, 395, 397, 400, 437, 439, 525, 1048
N6-acetyllysine	556
Phosphothreonine	588, 871, 1058, 1246
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2)	519, 547

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

8 pathways:

ID	Pathway	Evidence
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes	curated
R-HSA-74160	Gene expression (Transcription)	—
R-HSA-212436	Generic Transcription Pathway	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—
R-HSA-73857	RNA Polymerase II Transcription	—
R-HSA-3700989	Transcriptional Regulation by TP53	—

MSigDB gene sets: 410 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_DN, GOCC_SECRETORY_GRANULE, GOBP_NEGATIVE_REGULATION_OF_STEM_CELL_DIFFERENTIATION, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, MORF_ATRX, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, TGACCTY_ERR1_Q2, MORF_ESR1, CTATGCA_MIR153, RODRIGUES_NTN1_TARGETS_DN, MODULE_239, MORF_PPP5C, BLALOCK_ALZHEIMERS_DISEASE_UP, MORF_FANCG

GO Biological Process (23): alternative mRNA splicing, via spliceosome (GO:0000380), regulation of signal transduction (GO:0009966), hemopoiesis (GO:0030097), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of transcription by RNA polymerase II (GO:0006357), mRNA processing (GO:0006397), protein phosphorylation (GO:0006468), epidermal growth factor receptor signaling pathway (GO:0007173), RNA splicing (GO:0008380), positive regulation of macrophage chemotaxis (GO:0010759), positive regulation of telomere maintenance (GO:0032206), regulation of stress-activated MAPK cascade (GO:0032872), cellular response to amino acid starvation (GO:0034198), stress-activated MAPK cascade (GO:0051403), regulation of cytoskeleton organization (GO:0051493), regulation of cell cycle (GO:0051726), interleukin-34-mediated signaling pathway (GO:0061514), response to epidermal growth factor (GO:0070849), caveolin-mediated endocytosis (GO:0072584), regulation of Golgi inheritance (GO:0090170), positive regulation of macrophage proliferation (GO:0120041), regulation of early endosome to late endosome transport (GO:2000641)

GO Molecular Function (15): RNA binding (GO:0003723), protein kinase activity (GO:0004672), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), RNA polymerase II CTD heptapeptide repeat kinase activity (GO:0008353), protein kinase binding (GO:0019901), cyclin binding (GO:0030332), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein serine/threonine kinase activity (GO:0004674), MAP kinase activity (GO:0004707), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), phosphatase binding (GO:0019902)

GO Cellular Component (14): cyclin K-CDK13 complex (GO:0002945), extracellular region (GO:0005576), nucleus (GO:0005634), nucleoplasm (GO:0005654), cyclin/CDK positive transcription elongation factor complex (GO:0008024), nuclear speck (GO:0016607), nuclear cyclin-dependent protein kinase holoenzyme complex (GO:0019908), ficolin-1-rich granule lumen (GO:1904813), cyclin-dependent protein kinase holoenzyme complex (GO:0000307), early endosome (GO:0005769), late endosome (GO:0005770), Golgi apparatus (GO:0005794), caveola (GO:0005901), focal adhesion (GO:0005925)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Transcriptional Regulation by TP53	1
Innate Immune System	1
Immune System	1
RNA Polymerase II Transcription	1
Generic Transcription Pathway	1
Gene expression (Transcription)	1

GO top-level categories

showing 60 of 80 GO namespaces:

Category	Terms
protein serine/threonine kinase activity	3
transcription by RNA polymerase II	2
RNA processing	2
MAPK cascade	2
protein kinase activity	2
cyclin-dependent protein kinase holoenzyme complex	2
cellular anatomical structure	2
intracellular membrane-bounded organelle	2
endosome	2
mRNA splicing, via spliceosome	1
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
cell development	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
positive regulation of transcription by RNA polymerase II	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
mRNA metabolic process	1
phosphorylation	1
protein modification process	1
ERBB signaling pathway	1
positive regulation of leukocyte chemotaxis	1
regulation of macrophage chemotaxis	1
macrophage chemotaxis	1
regulation of granulocyte chemotaxis	1
positive regulation of macrophage migration	1
telomere maintenance	1
regulation of telomere maintenance	1
positive regulation of DNA metabolic process	1
positive regulation of chromosome organization	1
regulation of MAPK cascade	1
stress-activated MAPK cascade	1
regulation of stress-activated protein kinase signaling cascade	1
cellular response to starvation	1
response to amino acid starvation	1
stress-activated protein kinase signaling cascade	1
cytoskeleton organization	1
regulation of organelle organization	1
cell cycle	1
regulation of cellular process	1
cytokine-mediated signaling pathway	1
response to growth factor	1
endocytosis	1
vesicle-mediated transport	1
nucleic acid binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
cyclin-dependent protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
RNA polymerase II CTD heptapeptide repeat modifying activity	1
kinase binding	1
protein binding	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 9 of 53 annotations. The rest are phylogenetic / computational / electronic (IEA).

9 experimentally-supported GO terms:

GO term	NS	Evidence
hemopoiesis	BP	mutant phenotype
positive regulation of transcription by RNA polymerase II	BP	direct assay
positive regulation of transcription elongation by RNA polymerase II	BP	direct assay
regulation of signal transduction	BP	direct assay
cyclin K-CDK13 complex	CC	physical interaction
nuclear speck	CC	direct assay
RNA binding	MF	high-throughput assay
RNA polymerase II CTD heptapeptide repeat kinase activity	MF	direct assay
cyclin binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 1,712 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDK13	MMP23B	O75900	916
CDK13	MMP21	Q8N119	849
CDK13	CCNK	O75909	831
CDK13	CCNH	P51946	638
CDK13	CCNT1	O60563	632
CDK13	SUPT5H	O00267	583
CDK13	CCNT2	O60583	556
CDK13	CCNL1	Q9UK58	542
CDK13	CCNC	P24863	540
CDK13	POLR2A	P24928	540
CDK13	JAG2	Q9Y219	535
CDK13	CCNL2	Q96S94	519
CDK13	BCHE	P06276	497
CDK13	CTDP1	Q9Y5B0	494
CDK13	SUPT6H	Q7KZ85	460

IntAct

Human interaction partners of CDK13 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

11 partners by confidence:

Partner	Interaction type	MIscore	Records
CCNK	direct interaction	0.830	6
CDC37	physical association	0.560	1
H3-4	physical association	0.400	1
CHMP4A	physical association	0.370	2
CHMP5	physical association	0.370	1
CHMP6	physical association	0.370	1
PRPF40A	physical association	0.370	1
AIP	association	0.350	1
EEF2	association	0.350	1
H1-4	association	0.350	1
DISC1	physical association	0.000	1

BioGRID (233 interactions; top human partners by supporting records): CCNK (Affinity Capture-MS; 6 records), CDK12 (Affinity Capture-MS; 6 records), FKBP5 (Affinity Capture-MS; 4 records), HSP90AA1 (Affinity Capture-MS; 4 records), HSP90AB1 (Affinity Capture-MS; 4 records), BANF1 (Cross-Linking-MS (XL-MS); 3 records), DSTYK (Affinity Capture-MS; 3 records), FBXO11 (Affinity Capture-MS; 3 records), FBXO44 (Affinity Capture-MS; 3 records), HSP90AA4P (Affinity Capture-MS; 3 records), HSP90AA5P (Affinity Capture-MS; 3 records), HSP90AB3P (Affinity Capture-MS; 3 records), HSP90AB4P (Affinity Capture-MS; 3 records), KEAP1 (Affinity Capture-MS; 3 records), NEK3 (Affinity Capture-MS; 3 records)

SIGNOR signaling

showing 6 of 30 signaling interactions:

A	Effect	B	Mechanism
CDK13	“form complex”	CyclinK/CDK13	binding
CDK13	“up-regulates activity”	POLR2A	phosphorylation
CDK13	“up-regulates activity”	EIF4EBP1	phosphorylation
CDK13	“up-regulates activity”	EIF4B	phosphorylation
CDK13	“down-regulates quantity by destabilization”	SERINC5	phosphorylation
CCNO	“up-regulates activity”	CDK13	binding

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
CCNK-CDK13 complex	2	CCNK, CDK13

Disease & clinical

Genetic variants

Variant evidence for CDK13: 1,264 ClinVar records (82 pathogenic / likely pathogenic); 5 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

1,264 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	40
Likely pathogenic	42
Uncertain significance	612
Likely benign	365
Benign	75

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 82 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
375737	NM_003718.5(CDK13):c.2149G>A (p.Gly717Arg)	Pathogenic	criteria provided, multiple submitters, no conflicts	15
449224	NM_003718.5(CDK13):c.2141G>A (p.Gly714Asp)	Pathogenic	criteria provided, multiple submitters, no conflicts	4
423480	NM_003718.5(CDK13):c.2209C>T (p.Arg737Cys)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
1215514	NM_003718.5(CDK13):c.454C>T (p.Gln152Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
827814	NM_003718.5(CDK13):c.2194G>A (p.Ala732Thr)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
1299065	NM_003718.5(CDK13):c.2627C>T (p.Thr876Ile)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
1339033	NM_003718.5(CDK13):c.2563G>A (p.Asp855Asn)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
1691565	NM_003718.5(CDK13):c.2609A>G (p.Tyr870Cys)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
4293604	NM_003718.5(CDK13):c.2119ATC[1] (p.Ile708del)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
375738	NM_003718.5(CDK13):c.2140G>C (p.Gly714Arg)	Pathogenic	criteria provided, single submitter	2
422362	NM_003718.5(CDK13):c.2200A>G (p.Lys734Glu)	Pathogenic	criteria provided, single submitter	2
973023	NM_003718.5(CDK13):c.2511T>G (p.Asp837Glu)	Pathogenic	criteria provided, single submitter	2
987083	NM_003718.5(CDK13):c.1187del (p.Arg396fs)	Pathogenic	criteria provided, single submitter	1
1695188	NM_003718.5(CDK13):c.2227G>T (p.Glu743Ter)	Pathogenic	criteria provided, single submitter	1
2034771	NM_003718.5(CDK13):c.352_353insCGGGCGGA (p.Arg118fs)	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore CDK13’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 24 predictions of 1,536):

Position(s)	Effect	Δscore	Sites
7:39997622	donor_gain	1.0000
7:39997642	donor_gain	1.0000
7:39997661	donor_gain	1.0000
7:40001857	acceptor_gain	1.0000
7:40001859–40001860	acceptor_loss	1.0000	5
7:40002032–40002033	donor_loss	1.0000	3
7:40047811	acceptor_gain	1.0000
7:40047820	acceptor_gain	1.0000
7:40047878–40047879	donor_loss	1.0000	5
7:40062824–40062825	acceptor_loss	1.0000	5

AlphaMissense

3,481 missense substitutions predicted likely pathogenic (of 9,791 scored), across 778 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M799	9	0.988	1.000
M794	9	0.948	0.999
M767	9	0.937	0.999
M818	9	0.856	0.997
F745	8	1.000	1.000
H796	8	1.000	1.000
D797	8	1.000	1.000
D837	8	1.000	1.000
N842	8	1.000	1.000
D855	8	1.000	1.000
D896	8	1.000	1.000
H1018	8	1.000	1.000
D773	8	0.999	1.000
F791	8	0.999	1.000
H829	8	0.999	1.000
H835	8	0.999	1.000
F856	8	0.999	1.000
D1016	8	0.999	1.000
F780	8	0.998	1.000
F787	8	0.998	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Disease associations

OMIM: gene MIM:603309 | disease phenotypes: MIM:617360

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
congenital heart defects, dysmorphic facial features, and intellectual developmental disorder	Definitive	Autosomal dominant	3

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
syndromic intellectual disability	Definitive	AD

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (9 panels, 9 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

9 panels:

Panel	Rating
Cerebral malformation	green
DDG2P	green
Fetal anomalies	green
Hypotonic infant	green
Intellectual disability	green
Leukodystrophy, childhood onset	green
Malformations of cortical development	green
Paediatric disorders	green
Rare syndromic craniosynostosis or isolated multisuture synostosis	green

Mondo (4): congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (MONDO:0044302), syndromic intellectual disability (MONDO:0000508), neurodevelopmental disorder (MONDO:0700092), autism spectrum disorder (MONDO:0005258)

Orphanet (3): CDK13-related developmental delay-intellectual disability-facial dysmorphism-congenital heart defects syndrome (Orphanet:646278), Rare genetic syndromic intellectual disability (Orphanet:183763), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

showing 60 of 67 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000160	Narrow mouth
HP:0000200	Short lingual frenulum
HP:0000215	Thick upper lip vermilion
HP:0000219	Thin upper lip vermilion
HP:0000233	Thin vermilion border
HP:0000252	Microcephaly
HP:0000269	Prominent occiput
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000322	Short philtrum
HP:0000324	Facial asymmetry
HP:0000356	Abnormality of the outer ear
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000396	Overfolded helix
HP:0000414	Bulbous nose
HP:0000426	Prominent nasal bridge
HP:0000431	Wide nasal bridge
HP:0000486	Strabismus
HP:0000506	Telecanthus
HP:0000508	Ptosis
HP:0000574	Thick eyebrow
HP:0000581	Blepharophimosis
HP:0000582	Upslanted palpebral fissure
HP:0000691	Microdontia
HP:0000717	Autism
HP:0000750	Delayed speech and language development
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001270	Motor delay
HP:0001274	Agenesis of corpus callosum
HP:0001357	Plagiocephaly
HP:0001382	Joint hypermobility
HP:0001511	Intrauterine growth retardation
HP:0001561	Polyhydramnios
HP:0001629	Ventricular septal defect
HP:0001631	Atrial septal defect
HP:0002019	Constipation
HP:0002020	Gastroesophageal reflux
HP:0002079	Hypoplasia of the corpus callosum
HP:0002121	Generalized non-motor (absence) seizure
HP:0002162	Low posterior hairline
HP:0002212	Curly hair
HP:0002472	Small cerebral cortex
HP:0002553	Highly arched eyebrow
HP:0002572	Episodic vomiting
HP:0002650	Scoliosis
HP:0002714	Downturned corners of mouth
HP:0003298	Spina bifida occulta
HP:0003577	Congenital onset
HP:0004322	Short stature
HP:0005989	Redundant neck skin
HP:0006610	Wide intermamillary distance
HP:0006970	Periventricular leukomalacia
HP:0007413	Nevus flammeus of the forehead
HP:0010536	Central sleep apnea

GWAS associations

5 associations:

Study	Trait	p-value
GCST90002388_425	Lymphocyte count	2e-18
GCST90002400_193	Plateletcrit	3e-10
GCST90002389_248	Lymphocyte percentage of white cells	1e-9
GCST90002399_38	Neutrophil percentage of white cells	3e-9
GCST004751_14	Serum uric acid levels in response to allopurinol in gout	3e-6

EFO canonical traits (from GWAS)

5 canonical traits:

EFO ID	Trait name
EFO:0004761	uric acid measurement
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007985	platelet crit

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL1795192 (SINGLE PROTEIN), CHEMBL3559691 (PROTEIN FAMILY), CHEMBL4296067 (PROTEIN COMPLEX), CHEMBL4630753 (PROTEIN FAMILY), CHEMBL5169085 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 62,398 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

20 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL428690	ALVOCIDIB	3	28,145
CHEMBL3137331	DEFACTINIB	3	1,286
CHEMBL2103840	DINACICLIB	3	2,395
CHEMBL38380	FASUDIL	3	12,137
CHEMBL603469	LESTAURTINIB	3
CHEMBL223360	LINIFANIB	3	4,094
CHEMBL445813	AT-7519	2	2,733
CHEMBL215152	DEFOSBARASERTIB	2	381
CHEMBL103667	DORAMAPIMOD	2	1,746
CHEMBL1230609	FORETINIB	2	3,230
CHEMBL1276127	INDIRUBIN	2	183
CHEMBL5199065	ISTISOCICLIB	2	22
CHEMBL3544964	RAVOXERTINIB	2	1,317
CHEMBL384304	RG-547	2	93
CHEMBL2140408	AMG-900	1	708
CHEMBL574738	AST-487	1	468
CHEMBL296468	BMS-387032	1	2,127
CHEMBL1084546	PF-00562271	1	424
CHEMBL1230607	PHA-793887	1	316
CHEMBL3545083	RGB-286638	1	593

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CRK7 subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
CDK12 inhibitor 2	Inhibition	8.0	pIC50
YJZ5118	Inhibition	7.58	pIC50

Binding affinities (BindingDB)

141 measured of 212 human assays (214 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	KD	0.37 nM
CHEMBL4077071	IC50	2 nM
CEP-701	KD	3.4 nM
Staurosporine, 8	IC50	6.5 nM
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1’-propioloyl-1’,2’,3’,6’-tetrahydro-[2,4’- bipyridin]-5-yl)propanamide	IC50	7 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
2-(6-(1-acryloyl-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide	IC50	10 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide	EC50	10 nM	US-10787436: Inhibitors of cyclin-dependent kinase 7 (CDK7)
CHEMBL5182767	IC50	11 nM
CHEMBL5169449	IC50	12 nM
2-(4-(1-acryloyl-1,2,5,6-tetrahydropyridin-3-yl)-3-fluorophenyl)-N-(5- cyclopropyl-1H-pyrazol-3-yl)propanamide	IC50	14 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
N-[4-[[(2-hydroxy-1H-indol-3-yl)-phenylmethylidene]amino]phenyl]-N-methyl-2-(4-methylpiperazin-1-yl)acetamide	KI	15 nM	US-10981896: Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide	IC50	17 nM
CHEMBL5194202	IC50	20 nM
2-(1’-acryloyl-1’,2’,5’,6’-tetrahydro-[2,3’-bipyridin]-5-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide	IC50	23 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL5187378	IC50	23 nM
CHEMBL5203891	KD	27 nM
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[6-(1-prop-2-enoyl-3,6-dihydro-2H-pyridin-5-yl)-3-pyridinyl]propanamide	IC50	29 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
2-(1’-acryloyl-1’,2’,5’,6’-tetrahydro-[2,3’-bipyridin]-5-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)propanamide	IC50	30 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[6-(1-prop-2-enoyl-2,5-dihydropyrrol-3-yl)-3-pyridinyl]propanamide	IC50	32 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
N-(5-(3-benzyl-1-((1r,4r)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)-2-(4-(dimethylamino)piperidin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-(((1r,4r)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)-2-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-((1r,4r)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)-2-bromophenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-(((1r,4S)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)-2-((S)-3-methylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(2-(4-acetylpiperazin-1-yl)-5-(3-benzyl-1-((1r,4r)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-((1r,4R)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)ureido)-2-((1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-((1r,4S)-4-((5-chloropyridin-2-yl)amino)cyclohexyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(3-benzyl-1-((1r,4S)-4-((5-(trifluoromethyl)pyridin-2-yl)amino)cyclohexyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(1-((1r,4S)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-3-((S)-1-phenylethyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(1-((1r,4S)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-3-(2-fluorobenzyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(1-((1r,4S)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-3-(3-fluorobenzyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
N-(5-(1-((1r,4S)-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-3-(4-fluorobenzyl)ureido)-2-((S)-3,4-dimethylpiperazin-1-yl)phenyl)acrylamide	IC50	32.5 nM	US-20250100994: CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
2-(6-(1-acryloyl-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)propanamide	IC50	34 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
2-(1’-(but-2-ynoyl)-1’,2’,5’,6’-tetrahydro-[2,3’-bipyridin]-5-yl)-N-(5-cyclopropyl- 1H-pyrazol-3-yl)acetamide	IC50	37 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL5194833	IC50	38 nM
2-(1’-acryloyl-1’,2’,3’,6’-tetrahydro-[2,4’-bipyridin]-5-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide	IC50	40 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL6147235	EC50	40 nM
2-(1’-acryloyl-1’,2’,5’,6’-tetrahydro-[2,3’-bipyridin]-5-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)butanamide	IC50	41 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1’-propioloyl-1’,2’,5’,6’-tetrahydro-[2,3’- bipyridin]-5-yl)acetamide	IC50	49 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL4861833	IC50	49 nM
CHEMBL5193291	IC50	52 nM
CHEMBL4632717	IC50	53 nM
2-(6-(1-acryloylpyrrolidin-3-yl)pyridin-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide	IC50	55 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL6144395	IC50	55 nM
2-(6-(1-acryloylpiperidin-4-yl)pyridin-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide	IC50	58 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
(S)-2-(4-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(5-cyclopropyl- 1H-pyrazol-3-yl)propanamide	IC50	60 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
CHEMBL5191136	IC50	62 nM
2-(1’-acryloyl-1’,2’,3’,6’-tetrahydro-[2,4’-bipyridin]-5-yl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)propanamide	IC50	72 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
2-(4-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(5-cyclopropyl-1H- pyrazol-3-yl)propanamide	IC50	84 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
(E)-2-(1’-(but-2-enoyl)-1’,2’,5’,6’-tetrahydro-[2,3’-bipyridin]-5-yl)-N-(5- cyclopropyl-1H-pyrazol-3-yl)acetamide	IC50	94 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors
2-(6-(4-acryloylpiperazin-1-yl)pyridin-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide	IC50	99 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors

ChEMBL bioactivities

264 potent at pChembl≥5 of 266 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.05	IC50	0.9	nM	CHEMBL4797074
9.03	Kd	0.94	nM	AST-487
8.70	Kd	2	nM	CHEMBL4855324
8.68	EC50	2.1	nM	CHEMBL5178057
8.52	IC50	3	nM	CHEMBL4778361
8.52	IC50	3	nM	CHEMBL4781207
8.52	IC50	3	nM	CHEMBL4784925
8.49	Kd	3.2	nM	AT-7519
8.42	IC50	3.8	nM	CHEMBL4760738
8.41	IC50	3.9	nM	CHEMBL4744778
8.40	IC50	4	nM	CHEMBL4759298
8.40	IC50	4	nM	CHEMBL4791883
8.40	Kd	4	nM	CHEMBL4847754
8.40	IC50	4	nM	CHEMBL4847754
8.37	IC50	4.3	nM	CHEMBL4788447
8.35	EC50	4.5	nM	CHEMBL5205494
8.31	Kd	4.9	nM	CHEMBL4877117
8.30	IC50	5	nM	CHEMBL4740577
8.30	IC50	5	nM	CHEMBL4777358
8.30	IC50	5	nM	CHEMBL4786926
8.30	Kd	5	nM	CHEMBL4852083
8.30	Kd	5	nM	CHEMBL4877117
8.30	IC50	5	nM	CHEMBL4852083
8.30	IC50	5	nM	CHEMBL4877117
8.24	IC50	5.8	nM	CHEMBL4792293
8.22	IC50	6	nM	CHEMBL4778361
8.22	IC50	6	nM	CHEMBL4781207
8.22	IC50	6	nM	CHEMBL4778676
8.22	IC50	6	nM	CHEMBL4776295
8.22	Kd	6	nM	CHEMBL4868958
8.21	EC50	6.2	nM	CHEMBL5193459
8.16	IC50	6.9	nM	CHEMBL4778676
8.15	IC50	7	nM	CHEMBL4800122
8.15	IC50	7	nM	CHEMBL4784656
8.15	EC50	7.1	nM	CHEMBL5186403
8.15	IC50	7	nM	CHEMBL5917807
8.07	Kd	8.6	nM	CHEMBL4160662
8.07	EC50	8.5	nM	CHEMBL5182667
8.05	Kd	9	nM	CHEMBL4867928
8.04	IC50	9.22	nM	CHEMBL5929886
8.00	IC50	10	nM	CHEMBL4160662
8.00	IC50	10	nM	CHEMBL4799777
8.00	IC50	10	nM	CHEMBL4211454
8.00	IC50	10	nM	CHEMBL5193291
7.93	IC50	11.7	nM	CHEMBL4781668
7.92	IC50	12	nM	CHEMBL4778214
7.92	IC50	12	nM	CHEMBL5169449
7.92	IC50	12	nM	CHEMBL5998973
7.91	IC50	12.2	nM	CHEMBL6147235
7.90	EC50	12.5	nM	CHEMBL5200971

PubChem BioAssay actives

126 with measured affinity, of 721 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	624761: Binding constant for CDC2L5 kinase domain	kd	0.0009	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0021	uM
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	624761: Binding constant for CDC2L5 kinase domain	kd	0.0032	uM
4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazine-1-carboxamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0045	uM
N-[(5,6-dichloro-1H-benzimidazol-2-yl)methyl]-9-(1-methylpyrazol-4-yl)-2-morpholin-4-ylpurin-6-amine	1890148: Binding affinity to CDK13 (unknown origin) assessed as dissociation constant	kd	0.0049	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-3-oxo-1H-isoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0062	uM
2-[4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]piperazin-1-yl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]acetamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0071	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0085	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-(1-methyl-6-oxo-3-pyridinyl)phenyl]urea	1870804: Binding affinity to human CDK13 (694 to 1039 residues)/CyclinK (1 to 267 residues) expressed in baculovirus infected in Sf9 cells by Biolayer interferometry	kd	0.0086	uM
N-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidine-1-carbonyl]phenyl]prop-2-enamide	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.0092	uM
5-(2-aminoethylsulfanyl)-3-cyclobutyl-N-[(4-pyridin-2-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0120	uM
N-[4-[2-[2-[(5-cyclobutyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]imidazo[1,2-b]pyridazin-6-yl]-2-fluorophenyl]prop-2-enamide	2244260: Inhibition of CDK13 (unknown origin) using GSRTPMY-NH2 as substrate in presence of ATP by ADP-glo assay	ic50	0.0122	uM
3-[4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]piperazin-1-yl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]propanamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0125	uM
N-[1-benzyl-3-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-6-morpholin-4-yl-2-oxo-7,8,9,9a-tetrahydroperimidin-5-yl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0128	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-(1-methyl-6-oxo-3-pyridinyl)phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0149	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-(4-piperazin-1-ylphenyl)urea	1870804: Binding affinity to human CDK13 (694 to 1039 residues)/CyclinK (1 to 267 residues) expressed in baculovirus infected in Sf9 cells by Biolayer interferometry	kd	0.0170	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[(E)-3-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]prop-2-enoyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0207	uM
2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol	1424940: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0210	uM
4-N-[4-[5-(cyclopropylmethyl)-1-methylpyrazol-4-yl]-5-fluoropyrimidin-2-yl]cyclohexane-1,4-diamine	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0215	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0217	uM
5-(2-aminoethylsulfanyl)-3-cyclobutyl-N-[(4-pyrazol-1-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0220	uM
5-(2-aminoethylsulfanyl)-3-propan-2-yl-N-[(4-pyrazin-2-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0220	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	624761: Binding constant for CDC2L5 kinase domain	kd	0.0230	uM
N-[3-[[3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]phenyl]prop-2-enamide	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0293	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxyacetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0360	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	624761: Binding constant for CDC2L5 kinase domain	kd	0.0380	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0400	uM
N-[4-[(3R)-3-[[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]amino]piperidine-1-carbonyl]phenyl]prop-2-enamide	1652531: Inhibition of human CDK13/cyclin K using Pol2-CTD as substrate by [gamma-33P]ATP-based radioisotope filter binding assay	ic50	0.0490	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]pyrrolidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.0502	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1356600: Inhibition of N-terminal FLAG-tagged human full-length CDK13 (1 to 1512 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pre-incubated for 60 mins by LANCE Ultra assay	ic50	0.0570	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0668	uM
5-(2-aminoethylsulfanyl)-N-[(4-imidazol-1-ylphenyl)methyl]-3-propan-2-yl-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0670	uM
(E)-N-[4-[(3S)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1653046: Inhibition of CDK13 (unknown origin)	ic50	0.0690	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-[3-(dimethylamino)azetidin-1-yl]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0737	uM
1-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-2-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.0748	uM
1-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.0761	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-[2-(dimethylamino)ethyl-methylamino]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0793	uM
1-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.0794	uM
N-[5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]-2-[(3S)-3,4-dimethylpiperazin-1-yl]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0839	uM
1-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-2-methoxy-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.0954	uM
N-[3-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.0990	uM
1-[5-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-3,4-dihydro-1H-2,6-naphthyridin-2-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.1069	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	624761: Binding constant for CDC2L5 kinase domain	kd	0.1100	uM
(E)-N-[6-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-pyridinyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1200	uM
1-[[3-propan-2-yl-7-[(4-pyrazol-1-ylphenyl)methylamino]-2H-pyrazolo[4,3-d]pyrimidin-5-yl]sulfanyl]propan-2-ol	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.1220	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]phenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1230	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-fluorophenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1266	uM
2-N-[4-(3-aminopropylamino)phenyl]-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.1545	uM
N-[2-(4-acetylpiperazin-1-yl)-5-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]prop-2-enamide	2246319: Inhibition of CDK13/cyclin K (unknown origin) by ADP-Glo kinase assay	ic50	0.1640	uM
1-[4-[(3R)-3-[(5-chloro-4-methoxypyrimidin-2-yl)amino]pyrrolidin-1-yl]-2-morpholin-4-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]prop-2-en-1-one	2269957: Inhibition of CDK13/Cyclin K (unknown origin) using pS7-CTD peptide and ATP as substrate incubated for 120 mins by ADP-Glo reagent based luminescence analysis	ic50	0.1648	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium	affects reaction, decreases expression, increases abundance	2
Formaldehyde	increases expression, decreases expression	2
Valproic Acid	decreases expression, increases methylation	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
FR900359	affects phosphorylation	1
ginger extract	increases abundance, decreases expression	1
geldanamycin	increases expression	1
bisphenol A	decreases expression	1
lead acetate	increases expression, affects cotreatment	1
cypermethrin	decreases expression	1
zinc protoporphyrin	affects cotreatment, increases expression	1
sodium arsenite	increases expression	1
coumarin	decreases phosphorylation	1
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	increases expression	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases expression	1
polyhexamethyleneguanidine	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	decreases expression	1
Irinotecan	decreases expression	1
Leflunomide	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Caffeine	affects phosphorylation	1
Coumestrol	decreases expression	1
Doxorubicin	decreases expression	1
Emodin	decreases expression	1
Estradiol	affects expression	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Menthol	increases expression	1
Nicotine	increases expression	1
Oils, Volatile	decreases expression, increases abundance	1

ChEMBL screening assays

257 unique, capped per target: 250 binding, 7 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1174102	Binding	Inhibition of CDC2L5 at 10 uM	Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. — *Bioorg Med Chem Lett*
CHEMBL5445783	Functional	Affinity Phenotypic Cellular interaction: (In-Cell western blot (using MDA-MB-231 cells)) EUB0001632a CDK13	Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SI21	HAP1 CDK13 (-) 1	Cancer cell line	Male
CVCL_SI22	HAP1 CDK13 (-) 2	Cancer cell line	Male
CVCL_SI23	HAP1 CDK13 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00391261	Phase 4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	Phase 4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	Phase 4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	Phase 4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	Phase 4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	Phase 4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	Phase 4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	Phase 4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	Phase 4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	Phase 4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	Phase 4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	Phase 4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	Phase 4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	Phase 4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	Phase 4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	Phase 4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	Phase 4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	Phase 4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	Phase 4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	Phase 4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	Phase 4	RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT07770152	Phase 4	NOT_YET_RECRUITING	Semaglutide in Youth With Autism Spectrum Disorder
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT01302964	Phase 3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	Phase 3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	Phase 3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	Phase 3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	Phase 3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	Phase 3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	Phase 3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	Phase 3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	Phase 3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	Phase 3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	Phase 3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	Phase 3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	Phase 3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	Phase 3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	Phase 3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	Phase 3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	Phase 3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	Phase 3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	Phase 3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06333964	Phase 3	COMPLETED	A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
NCT07257939	Phase 3	NOT_YET_RECRUITING	NTI164 in Autism Spectrum Disorder
NCT07655115	Phase 3	RECRUITING	Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00251303	Phase 2	COMPLETED	Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
NCT00614198	Phase 2	COMPLETED	ScanBrit Dietary Intervention in Autism
NCT00619190	Phase 2	COMPLETED	Study of Aripiprazole to Treat Children and Adolescents With Autism
NCT00709202	Phase 2	COMPLETED	Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
NCT00846547	Phase 2	COMPLETED	Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
NCT01064973	Phase 2	TERMINATED	An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
NCT01170325	Phase 2	WITHDRAWN	A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for CDK13 across ~30M SureChEMBL compounds — explore on Sugi Predict.